FDA Warns of Hepatitis B Reactivation Risk in Patients Treated for Hepatitis C

Drug Industry Daily
The FDA issued a warning about the risk of hepatitis B virus (HBV) becoming an active again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for the hepatitis C virus.

To View This Article:


Subscribe To Drug Industry Daily